Koning Catherina J M, Jonkers Daisy M A E, Stobberingh Ellen E, Mulder Linda, Rombouts Frans M, Stockbrügger Reinhold W
Division of Gastroenterology-Hepatology, University Hospital Maastricht, Maastricht, The Netherlands.
Am J Gastroenterol. 2008 Jan;103(1):178-89. doi: 10.1111/j.1572-0241.2007.01547.x. Epub 2007 Sep 25.
One of the side effects of antimicrobial therapy is a disturbance of the intestinal microbiota potentially resulting in antibiotic-associated diarrhea (AAD). In this placebo-controlled double-blind study, the effect of a multispecies probiotic on the composition and metabolic activity of the intestinal microbiota and bowel habits was studied in healthy volunteers taking amoxycillin.
Forty-one healthy volunteers were given 500 mg amoxycillin twice daily for 7 days and were randomized to either 5 g of a multispecies probiotic, Ecologic AAD (10(9) cfu/g), or placebo, twice daily for 14 days. Feces and questionnaires were collected on day 0, 7, 14, and 63. Feces was analyzed as to the composition of the intestinal microbiota, and beta-glucosidase activity, endotoxin concentration, Clostridium difficile toxin A, short chain fatty acids (SCFAs), and pH were determined. Bowel movements were scored according to the Bristol stool form scale.
Mean number of enterococci increased significantly from log 4.1 at day 0 to log 5.8 (day 7) and log 6.9 (day 14) cfu/g feces (P < 0.05) during probiotic intake. Although no other significant differences were observed between both intervention groups, within each group significant changes were found over time in both microbial composition and metabolic activity. Moreover, bowel movements with a frequency >or=3 per day for at least 2 days and/or a consistency >or=5 for at least 2 days were reported less frequently in the probiotic compared to the placebo group (48%vs 79%, P < 0.05).
Apart from an increase in enterococci no significant differences in microbial composition and metabolic activity were observed in the probiotic compared with the placebo group. However, changes over time were present in both groups, which differed significantly between the probiotic and the placebo arm, suggesting that the amoxycillin effect was modulated by probiotic intake. Moreover, the intake of a multispecies probiotic significantly reduced diarrhea-like bowel movements in healthy volunteers receiving amoxycillin.
抗菌治疗的副作用之一是肠道微生物群紊乱,可能导致抗生素相关性腹泻(AAD)。在这项安慰剂对照双盲研究中,研究了一种多菌种益生菌对服用阿莫西林的健康志愿者肠道微生物群的组成和代谢活性以及排便习惯的影响。
41名健康志愿者每天两次服用500mg阿莫西林,持续7天,并随机分为两组,一组每天两次服用5g多菌种益生菌Ecologic AAD(10⁹ cfu/g),另一组服用安慰剂,持续14天。在第0、7、14和63天收集粪便和问卷。分析粪便的肠道微生物群组成,并测定β-葡萄糖苷酶活性、内毒素浓度、艰难梭菌毒素A、短链脂肪酸(SCFAs)和pH值。根据布里斯托大便形态量表对排便情况进行评分。
在摄入益生菌期间,粪肠球菌的平均数量从第0天的log 4.1显著增加到第7天的log 5.8和第14天的log 6.9 cfu/g粪便(P < 0.05)。虽然两个干预组之间未观察到其他显著差异,但每组内微生物组成和代谢活性均随时间发生了显著变化。此外,与安慰剂组相比,益生菌组中每天排便频率≥3次且持续至少2天和/或大便质地≥5级且持续至少2天的情况报告较少(48%对79%,P < 0.05)。
与安慰剂组相比,除了肠球菌增加外,益生菌组在微生物组成和代谢活性方面未观察到显著差异。然而,两组均随时间发生了变化,益生菌组和安慰剂组之间存在显著差异,这表明益生菌的摄入调节了阿莫西林的作用。此外,多菌种益生菌的摄入显著减少了服用阿莫西林的健康志愿者的腹泻样排便。